EU/3/02/121
About
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in Septebmer 2017 at the end of the 10-year period of market exclusivity.
On 13 November 2002, orphan designation (EU/3/02/121) was granted by the European Commission to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, for 5-aminolevulinic acid hydrochloride for the intra-operative photodynamic diagnosis of residual glioma.
5-aminolevulinic acid hydrochloride has been authorised in the EU as Gliolan since 7 September 2007.
Key facts
Active substance |
5-aminolevulinic acid hydrochloride
|
Medicine name |
Gliolan
|
Disease / condition |
Intra-operative photodynamic diagnosis of residual glioma
|
Date of first decision |
14/11/2002
|
Outcome |
Expired
|
EU designation number |
EU/3/02/121
|
Sponsor's contact details
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
D-22880 Wedel
Germany
Tel. + 49 4103 8006 0
Fax + 49 4103 8006 100
E-mail: contact@medac.de
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.